- Home
- FGEN
FGEN
FibroGen Inc
as 04-23-2025 4:00pm EST
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
| Founded: | 1993 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 33.5M | IPO Year: | 2014 |
| Target Price: | $10.00 | AVG Volume (30 days): | 899.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.18 - $1.74 | Next Earning Date: | 05-05-2025 |
| Revenue: | $29,621,000 | Revenue Growth: | -36.71% |
| Revenue Growth (this year): | 232.81% | Revenue Growth (next year): | 9.16% |
Stock Insider Trading Activity of FibroGen Inc (FGEN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Wettig Thane | FGEN | CEO | Mar 24 '25 | Buy | $0.35 | 145,000 | $50,663.00 | 543,329 | |
| Schoeneck James A | FGEN | Director | Mar 20 '25 | Buy | $0.35 | 300,000 | $105,040.00 | 323,722 |
Latest FibroGen Inc News
FGEN Breaking Stock News: Dive into FGEN Ticker-Specific Updates for Smart Investing
GlobeNewswire
21 days ago
FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
a month ago
FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology
Simply Wall St.
a month ago
FibroGen Full Year 2024 Earnings: Beats Expectations
Thomson Reuters StreetEvents
a month ago
Q4 2024 FibroGen Inc Earnings Call
GuruFocus.com
a month ago
FibroGen Inc (FGEN) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines with ...
Associated Press Finance
a month ago
FibroGen: Q4 Earnings Snapshot
GlobeNewswire
a month ago
FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
2 months ago
FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results
Compare FGEN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FGEN FibroGen Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.